Pharmaceutical companies, like any other sophisticated commercial entities, are subject to the risk of insolvency and may become participants in formal bankruptcy proceedings.

A pharmaceutical organization is defined as an entity engaged in pharmaceutical activities. This broad category encompasses the wholesale trade of medicinal products, their storage, transportation, and retail distribution—including distance selling (e-commerce)—as well as the dispensing, manufacturing, and compounding of medications.

While economic sanctions and shifting trade dynamics initially posed significant solvency risks for the industry, the landscape has evolved. Previously, the Russian pharmaceutical sector maintained a high degree of dependence on foreign partners. However, the critical need to ensure an uninterrupted supply of essential medications has catalyzed the growth of domestic Life Sciences companies capable of meeting market demand.

Despite this localized growth and the pivot toward procurement from friendly jurisdictions, insolvency cases involving pharmaceutical entities remain a prominent feature of the judicial landscape.

Notable Precedents in Pharmaceutical Insolvency

In recent years, several high-profile bankruptcy cases have shaped the legal standards within the pharmaceutical industry. Representative matters include:

1. The insolvency proceedings of JSC Scientific-Production Concern "ESKOM";
2. The bankruptcy of "Spektr" (formerly operating as "Nativa" until mid-2022);
3. The liquidation and creditor claims involving "Godovalov" LLC, among others.

Legal Framework for Pharmaceutical Bankruptcy Proceedings

The legislative framework does not currently provide for a separate, sector-specific statute governing pharmaceutical bankruptcy. Consequently, insolvency procedures in the Life Sciences sector are conducted under the general provisions of the Law on Insolvency (Bankruptcy).

Under the general rule, a legal entity is deemed insolvent if it is unable to satisfy creditor claims regarding monetary obligations, severance pay, or labor remuneration, or to fulfill mandatory tax and duty payments within three months of the due date. Bankruptcy proceedings may be initiated in a Commercial (Arbitration) Court provided that the aggregate claims against the debtor total no less than 2,000,000 Russian Rubles, unless otherwise specified by statute.

The following parties possess the legal standing to file a bankruptcy petition:

1. The debtor entity (voluntary filing);
2. Secured and unsecured bankruptcy creditors;
3. Authorized regulatory and governmental bodies;
4. Current or former employees holding claims for unpaid wages or severance benefits.

The Bankruptcy Moratorium and Its Impact on Life Sciences

Specific political and economic conditions may trigger a government-imposed moratorium on bankruptcy filings. To ensure economic stability during exceptional circumstances—such as industrial disasters, natural catastrophes, or extreme currency volatility—the Government of the Russian Federation has the authority to suspend the initiation of bankruptcy cases by creditors for a specified period.

In the pharmaceutical sector, such moratoria were implemented in 2020 during the global pandemic and again in 2022 in response to international sanctions. During a moratorium, any bankruptcy petitions filed by creditors against protected entities are returned by the court. This protection also extends to petitions filed just prior to the moratorium that had not yet been formally accepted for review.

Furthermore, the court may terminate bankruptcy proceedings under several conditions, including:

1. The successful restoration of the debtor’s solvency during financial recovery or external management phases;
2. The execution and court approval of a formal settlement agreement;
3. The dismissal of the petitioner’s claims during the supervision stage;
4. The formal withdrawal of claims by all participating creditors;
5. The full satisfaction of all claims included in the creditor registry;
6. An insufficiency of estate assets to cover court costs and the bankruptcy trustee’s remuneration.

Specialized Legal Services: Pharmaceutical Insolvency and Restructuring

1. Providing strategic legal counsel on all phases of pharmaceutical bankruptcy and reorganization.
2. Drafting and managing the complex documentation required for formal insolvency filings.
3. Representing the interests of debtors, creditors, and stakeholders in pharmaceutical-specific bankruptcy litigation and out-of-court restructuring.